AustraliaHealth

Echo IQ (ASX: EIQ) announced an expanded agreement to distribute its AI-driven heart failure solution, EchoSolv HF.

Cyclopharm (ASX:CYC) announced a new multi-site agreement with Northwestern Memorial HealthCare, a premier academic health system based in Chicago.

Radiopharm Theranostics (ASX:RAD) said its novel imaging agent, RAD 101, achieved its primary endpoint in 90% of patients during a Phase 2b interim analysis.

Melbourne-based Amplia Therapeutics (ASX:ATX) announced a clinical breakthrough in the treatment of advanced pancreatic cancer.

Enlitic (ASX:ENL) announced the signing of a data migration contract valued at US$1.5 million with Penn Medicine Doylestown Health.

Nexsen (ASX:NXN) completed a pre-submission meeting with the US Food and Drug Administration.

Paradigm Biopharmaceuticals (ASX:PAR) has bolstered its international clinical presence with the activation of a new trial site in Hong Kong.

Immutep (ASX:IMM), a pioneer in LAG-3 immunotherapy, has reached a milestone in the treatment of autoimmune diseases.

Racura Oncology (ASX:RAC) announced the dosing of the third patient in its CPACS Phase 1 clinical trial.

Nexalis Therapeutics (ASX:NX1) has commenced dosing in its Phase 1 clinical trial of IRX-616a.

Firebrick Pharma (ASX:FRE) has secured a key patent in the Philippines for Nasodine.

Vitura Health (ASX:VIT) announced a binding commercial distribution agreement with MedReleaf Australia.